ChemicalBook >> CAS DataBase List >>Vinorelbine tartrate

Vinorelbine tartrate

CAS No.
125317-39-7
Chemical Name:
Vinorelbine tartrate
Synonyms
NAVELBINE;VINORELBINE DITARTRATE;NVB;VINORELBINE BITARTRATE;c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy;Vinorelbin Tartrate;VINORELBINE TARTRATE USP STANDARD;3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate;(2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester;KW-2307
CBNumber:
CB8761554
Molecular Formula:
C53H66N4O20
Molecular Weight:
1079.11
MDL Number:
MFCD03613607
MOL File:
125317-39-7.mol
MSDS File:
SDS
Last updated:2023-09-08 13:28:03

Vinorelbine tartrate Properties

Melting point 181-183°C
storage temp. 2-8°C
solubility H2O: 10 mg/mL
form powder
color off-white
Stability Light Sensitive, Temperature Sensitive
InChIKey PMDHUNWDGZSEMN-WTUOTUPFSA-N
CAS DataBase Reference 125317-39-7(CAS DataBase Reference)
NCI Dictionary of Cancer Terms vinorelbine tartrate
FDA UNII 253GQW851Q
NCI Drug Dictionary vinorelbine tartrate

SAFETY

Risk and Safety Statements

Symbol(GHS)  GHS hazard pictograms
GHS07
Signal word  Warning
Hazard statements  H317
Precautionary statements  P280
Hazard Codes  Xi
Risk Statements  43
Safety Statements  26-36
RIDADR  UN 1544PSN1 6.1 / PGII
WGK Germany  3
HS Code  29339900
NFPA 704
0
2 0

Vinorelbine tartrate price More Price(46)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Sigma-Aldrich Y0001939 Vinorelbine for peak identification B European Pharmacopoeia (EP) Reference Standard 125317-39-7 Y0001939 $150 2024-03-01 Buy
Sigma-Aldrich Y0001938 Vinorelbine for peak identification A European Pharmacopoeia (EP) Reference Standard 125317-39-7 Y0001938 $176 2024-03-01 Buy
Sigma-Aldrich V2264 Vinorelbine ditartrate salt hydrate ≥98% (HPLC), powder 125317-39-7 5mg $114 2024-03-01 Buy
Sigma-Aldrich PHR3160 Vinorelbine Tartrate pharmaceutical secondary standard, certified reference material 125317-39-7 500MG $936 2024-03-01 Buy
Sigma-Aldrich 1714506 Vinorelbine tartrate 125317-39-7 200mg $4200 2024-03-01 Buy
Product number Packaging Price Buy
Y0001939 Y0001939 $150 Buy
Y0001938 Y0001938 $176 Buy
V2264 5mg $114 Buy
PHR3160 500MG $936 Buy
1714506 200mg $4200 Buy

Vinorelbine tartrate Chemical Properties,Uses,Production

Overview

Vinorelbine belongs to vinblastine derivatives, its action is similar to vincristine. It is first marketed in 1989 in France. The main role is to combine tubulin, consequently, it causes microtubule formation disorder during cells mitosis.
Vinorelbine belongs to cycle specific drugs, it is used clinically in the treatment of non-small cell lung cancer (NSCLC) and breast cancer, ovarian cancer, head and neck squamous cell carcinoma, leukemia. In addition,it also has a strong inhibitory effect on small cell lung cancer, colon cancer, brain tumors, malignant melanoma.

Pharmacological effects

Vinorelbine tartrate is the tartrate form of vinorelbine ,it is a semi-synthetic  vincristine compound, it belongs to M phase specific drugs, mechanism of action is similar to vincristine . Mainly it , by selectively blocking mitotic cell tubulin polymerization to form microtubule and  inducing tubulin depolymerization , impedes spindle microtubules,and it makes cell division stop  in the middle, and it has few effect on the synthetic tubulin in the shaft of nerve cells. Since NVB affinity for axonal microtubules is poor, only when there is a high concentration of it ,it has effect on axonal , so it has the lower neurotoxicity than other vincristine drugs,and it  has a greater therapeutic index. Human pharmacokinetics of vinorelbine show that after intravenous administration there is a three-compartment model, the volume  of distribution is large , PPB is up to 50% to 80%, plasma clearance rate is high, the terminal elimination phase T1/2 is 40 h, it has a rapid tissue distribution, concentration in tissues is significantly higher than vincristine (VCR), vindesine (VDS). Plasma clearance is 0.8 L/(kg • h),it is mainly through biliary secretion, and it is excreted with the feces, urine excretion accounts for 10% to 15%.It has a higher efficacy and less adverse reactions of the nervous system.

Clinical evaluation

Numerous clinical studies have shown that vinorelbine is one of the most effective drugs for the treatment of non-small cell lung cancer and breast cancer, single agent response rate is 14% to 35% and 30% to 60% respectively. And DDP combination chemotherapy in NSCLC and with doxorubicin combination therapy of breast cancer, efficiency is up to 30% to 50% and 50% to 77%, respectively. It has a good effect on ovarian cancer, malignant lymphoma, head and neck cancer, esophageal cancer.

Adverse reactions

  • Vinorelbine hematologic toxicity is dose-limiting , mainly it is neutropenia, which mostly restore  within 7d, it has a certain influence on red blood cells , thrombocytopenia and anemia incidence is less than 2%.
  • Neurotoxicity mainly performs as tendon reflexes (about 25%), occasional paresthesia, few patients may have gastrointestinal autonomic nerve paralysis induced constipation (17%~41%),  paralytic ileus is rare  , 2% 6% of the patients suffer finger (toe) numb, but the incidence is much lower than the VCR and VDS.
  • Incidence of gastrointestinal side effects is less than 10%. Occasionally, nausea, vomiting, dyspnea, and bronchospasm, often occur in a few minutes or several hours after treatment . Alopecia incidence is less than 10%.
  • Vinorelbine drug extravasation into the surrounding tissue can cause burning, injection site phlebitis, local tissue necrosis, ulceration, cellulitis.
  • Myelosuppression is dose-limiting toxicity. 3 to 5 days after the medication, transient myelosuppression can occur, usually it can recover within 10 days, attention should be paid to prevent infection. Neurotoxicity is visible.

Chemical properties

White or almost white powder or crystalline powder, odorless.

Application

Antineoplastic agents

Chemical Properties

Pale Yellow Powder

Uses

Vinorelbine Bitartrate is an antineoplastic.

Definition

ChEBI: The L-(+)-tartrate salt of vinorelbine.

brand name

Navelbine (Pierre).

General Description

Vinorelbine ditartrate is available in 1- and 5-mL vials at aconcentration of 10 mg/mL for IV use. It is FDA approvedfor the treatment of NSCLC. The agent has also been usedin treating metastatic breast cancer, cervical cancer, uterinecancer, and lung cancer especially in older patients or thosewith physical difficulties. Vinorelbine is the most lipophilicof the vinca alkaloids because of modifications of thecatharanthine ring system and dehydration of the piperidinering. This allows the agent to be quickly taken up into cellsincluding lung tissue where concentrations are 300-foldhigher than plasma concentrations. This is 3 to 13 timeshigher than the lung concentrations seen with vincristine.The agent is highly protein bound (80%–91%) and metabolizedby CYP3A. The major metabolite seen is the 4-Odesacetylderivative, which is equally active with the parentbut only formed in small quantities. The agent is eliminatedprimarily (33%–88%) in the bile with some appearing inthe urine (16%–30%). The elimination half-life is 27 to43 hours. The toxicities seen for vinorelbine includemyelosuppression, which is dose limiting but ceases upondiscontinuation of drug. This is most commonly seen as aneutropenia, and patient’s neutrophil count should be monitoredprior to and during therapy to decrease the chanceof infection. Additional toxicities include nausea/vomiting,elevation of liver function tests, alopecia, generalized fatigue,and inappropriate secretion of antidiuretic hormone.Neurotoxicity is seen with vinorelbine but occurs to a lesserdegree compared with other vinca alkaloids because of itsdecreased affinity for axonal microtubules.

Biological Activity

Selective mitotic microtubule antagonist that exhibits > 20 fold selectivity over axonal microtubules. Inhibits proliferation of multiple human tumor cell lines (IC 50 = 1.25 nM in HeLa cells) and blocks metaphase/anaphase transition by suppression of microtubule dynamics (IC 50 = 3.8 nM). Reduces spindle length by 29% and inhibits microtubule polymerization at micromolar concentrations.

Biochem/physiol Actions

Vinorelbine is a potent anti-mitotic, anti-tumor agent. Vinorelbine inhibits microtubule assembly. Low neurotoxicity is related to its higher affinity for mitotic microtubules than for axonal microtubules.

Vinorelbine tartrate Preparation Products And Raw materials

Raw materials

Preparation Products

Global( 525)Suppliers
Supplier Tel Email Country ProdList Advantage
Hebei Mojin Biotechnology Co., Ltd
+86-13288715578 +86-13231137666 sales@hbmojin.com China 12409 58
Shaanxi Haibo Biotechnology Co., Ltd
+86-02963020060 +86-18629295024 hibo06@xaltbio.com China 1000 58
Anhui Ruihan Technology Co., Ltd
+8617756083858 daisy@anhuiruihan.com China 994 58
Shanghai Daken Advanced Materials Co.,Ltd
+86-371-66670886 info@dakenam.com China 14770 58
Hangzhou FandaChem Co.,Ltd.
008657128800458; +8615858145714 fandachem@gmail.com China 9359 55
Nanjing Finetech Chemical Co., Ltd.
025-85710122 17714198479 sales@fine-chemtech.com CHINA 885 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795 ivan@atkchemical.com China 32480 60
Shanghai Zheyan Biotech Co., Ltd.
18017610038 zheyansh@163.com CHINA 3620 58
career henan chemical co
+86-0371-86658258 sales@coreychem.com China 29919 58
Chengdu GLP biotechnology Co Ltd
028-87075086 13350802083 scglp@glp-china.com CHINA 1824 58

View Lastest Price from Vinorelbine tartrate manufacturers

Image Update time Product Price Min. Order Purity Supply Ability Manufacturer
Vinorelbine tartrate  pictures 2024-03-16 Vinorelbine tartrate
125317-39-7
US $0.00 / KG 100g 98%+ 100kg WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Vinorelbine tartrate pictures 2024-03-16 Vinorelbine tartrate
125317-39-7
US $0.00 / KG 100g 98%+ 100kg WUHAN CIRCLE POWDER TECHNOLOGY CO.,LTD
Vinorelbine (ditartrate) pictures 2024-01-12 Vinorelbine (ditartrate)
125317-39-7
US $1.00 / mg 100mg 0.99 5ton/month ANHUI SHENGZHIKAI BIOTECHNOLOGY CO.,LTD

Vinorelbine tartrate Spectrum

VINORELBINEDITARTRATE SALT HYDRATE VINORELBINE TARTRATE, NAVELBINE VINORELBINE RELATED COMPOUND A4-O-DEACETYLVINORELBINE TARTRATE USP STANDARD VINORELBINE TARTRATE, USP VinorelbineTartrateUsp28 butanedioate(1:2) NAVELBINE TARTRATE VINORELBINE DITARTARIC ACID VINORELBINE DITARTRATE SALT VINORELBINE TARTRATE VINORELBINE(RG) Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12b,19a)-, (2R,3R)-2,3-dihydroxybutanedioate (1:2) (salt) Aspidospermidine-3-carboxylic acid, 4-(acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methyl-, methyl ester, (2b,3b,4b,5a,12R,19a)-, (2R,3R)-2,3-dih C'-Norvincaleukoblastine, 3',4'-didehydro-4'-deoxy-, [R-(R*,R*)]-2,3-dihydroxybutanedioate (1:2) (salt) Navelbine ditartrate Nor-5'-anhydrovinblastine ditartrate 5'-NORANHYDROVINOBLASTINE TARTRATE 3',4'-DIDEHYDRO-4'-DEOXY-C'-NORVINCALEUKOBLASTINE [R-(R*,R*)-2-3-DIHYDROXYBUTANEDIOATE (1:2) SALT] Pacilitaxel Vinorelbine ditartrate, Vinorelbine bitartrate, VRLB,KW – 2307 NVB KW-2307 Vinorelbine Bitartarate Vinorelbine ditartrate salt hydrate,3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartr Vinorelbine Tartrate (200 mg) Methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(1R,12S,14R)-16-ethyl-12-(Methoxycarbonyl)-1,10-diazatetracyclo[12.3.1.0^{3,11}.0^{4,9}]octadeca-3(11),4(9),5,7,15-pentaen-12-yl]-10-hydroxy-5-Methoxy-8-Methyl-8,16-diazapentacyclo[10.6.1.0^{1,9}.0 Vinorelbine ditartate lbine Ditartrate Vinoreline Tartrate 5μ-Noranhydrovinoblastine tartrate, KW-2307, Navelbine tartrate, NVB, 3μ,4μ-Didehydro-4μ-deoxy-Cμ-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt] Vinorelbine hydrate ditartrate salt Vinorelbine Tartrate USP/EP 3',4'-Didehydro-4'-deoxy-C'-norvincaleukoblastine Ditartrate Eunades Vinorelbin artrate vinorelbine L-tartrate Vinorelbine Ditartrate salt hydrate, ≥98%(HPLC) Vinorelbine tartrate CRS Vinorelbine tartrate cas 125317-39-7 inorelbine tartrate Vinorelbine tartrate USP/EP/BP Vinorelbine Bitartrate (10mM in DMSO) Vinorelbine ditartrate (KW-2307) Vinorelbine DitartrateQ: What is Vinorelbine Ditartrate Q: What is the CAS Number of Vinorelbine Ditartrate Q: What is the storage condition of Vinorelbine Ditartrate Q: What are the applications of Vinorelbine Ditartrate Vinorelbine-D3 DitartrateQ: What is Vinorelbine-D3 Ditartrate Q: What is the CAS Number of Vinorelbine-D3 Ditartrate Vinorelbine Tartrate (1714506) 3′,4′-Didehydro-4′-deoxy-C′-norvincaleukoblastine [R-(R*,R*)-2-3-dihydroxybutanedioate (1:2)salt], 5′-Noranhydrovinoblastine tartrate, KW-2307, NVB, Navelbine tartrate VINORELBINE TARTRATE USP STANDARD c’-norvincaleukoblastine,3’,4’-didehydro-4’-dioxy-,(r-(r*,r*))-2,3-dihydroxy NVB NAVELBINE VINORELBINE BITARTRATE VINORELBINE DITARTRATE Vinorelbin Tartrate (2β,3β,4β,5α,12R,19α)-4-(Acetyloxy)-6,7-didehydro-15-[(2R,6R,8S)-4-ethyl-1,3,6,7,8,9-hexahydro-8-(methoxycarbonyl)-2,6-methano-2H-azecino[4,3-b]indol-8-yl]-3-hydroxy-16-methoxy-1-methylaspidospermidine-3-carboxylicacidmethylester Atorvastatin Impurity 145 125317-39-7 C49H60N4O14 C45H54N4O82C4H6O6C